Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Quadrivalent Market Growth From $10.44 Billion In 2026 To $15.37 Billion By 2030 At A CAGR Of 10.1%
The quadrivalent market has experienced robust growth over recent years. Its value is projected to climb from $9.51 billion in 2025 to $10.44 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.8%. Multiple factors have driven this historical expansion, including a rising incidence of influenza, government-led vaccination initiatives, breakthroughs in vaccine research, heightened public awareness around flu prevention, and the early uptake of quadrivalent vaccines within developed economies.
The quadrivalent market is projected to experience substantial expansion in the coming years, reaching an estimated value of $15.37 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.1%. This anticipated growth during the forecast period is fueled by several key factors, including a heightened need for more comprehensive influenza protection, breakthroughs in vaccine delivery methods, the enlargement of vaccination initiatives in developing nations, greater financial commitments to biotechnology and precision medicine, as well as advantageous reimbursement policies and governmental backing. Notable trends shaping the forecast period involve the optimization of vaccine formulations, the extension of immunization programs to cover broader age groups, advancements in cold chain logistics and distribution systems, enhancements in coverage for multiple influenza strains, and a strong emphasis on meeting regulatory standards and ensuring quality assurance.
Download A Free Sample Report For Comprehensive Market Insights:
Quadrivalent Market Industry Drivers: What Is Driving Revenue Growth?
The global expansion of immunization coverage is anticipated to boost the quadrivalent market. Immunization coverage measures the percentage of a population that has received particular vaccines or a recommended set of vaccines within a defined period. As immunization coverage increases, it fuels higher demand for vaccines, and quadrivalent vaccines—which shield against four strains—are often included in standard vaccination schedules to tackle multiple diseases with a single dose. For example, in July 2025, the World Health Organization, a Switzerland-based international public health body, reported that global coverage for the first dose of the HPV vaccine among girls rose from 27% in 2023 to 31% in 2024. Consequently, the ongoing rise in immunization coverage worldwide will propel quadrivalent market growth in the future.
Quadrivalent Market Segment Performance And Strategic Opportunities
The quadrivalent market covered in this report is segmented –
1) By Type: Intradermal Shot, Intramuscular Injection, Nasal Spray
2) By Technology: Conjugated, Live, Inactivated, Recombinant, Toxoid, Other Technologies
3) By Disease: Cancer, Hepatitis, Pneumococcal Disease, COVID-19, Influenza, Human Papilloma Virus, Meningococcal Disease, Polio, Rotavirus, Other Diseases
4) By Age Group: Pediatric, Adult
5) By Distribution Channel: Hospital And Pharmacy, Government Suppliers, Other Channels (NGOs)
Subsegments:
1) By Intradermal Shot: Standard Intradermal Injection, Needle-Free Intradermal Delivery
2) By Intramuscular Injection: Standard Intramuscular Injection, Adjuvanted Intramuscular Injection
3) By Nasal Spray: Live Attenuated Nasal Spray, Inactivated Nasal Spray
Quadrivalent Market Growth Trends: What Is Influencing The Future Outlook?
Major players in the quadrivalent market are prioritizing safer and more innovative vaccine delivery methods, including nano-particle technology, to boost their revenue streams. This technology replicates the virus’s outer structure through virus-like particles (VLPs) that lack live genetic material, thereby improving safety and strengthening immune responses. For example, in March 2024, Cadila Pharmaceuticals, a pharmaceutical firm based in India, introduced the advanced Quadrivalent Influenza Vaccine, a cutting-edge immunization designed to protect against four distinct influenza virus strains: two A strains (H1N1 and H3N2) and two B strains. By targeting a wider array of circulating flu viruses, this quadrivalent formulation increases vaccine effectiveness, proving particularly valuable during flu seasons. The aQIV is engineered to elicit a robust immune reaction, thereby lowering the rates of influenza-related illness and death. Its creation underscores continuous efforts to enhance public health outcomes amid evolving viral threats.
Quadrivalent Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the quadrivalent market are AstraZeneca Plc, Serum Institute of India Private Limited, Sanofi S.A., GlaxoSmithKline Plc, CSL Limited, Bharat Biotech International Limited, Hualan Biological Engineering Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Pfizer Inc., Walvax Biotechnology Co. Ltd., Chongqing Zhifei Biological Products Co. Ltd., Biological E. Limited, GSK Biologicals SA, Institute of Vaccines and Biological Products Chinese Academy of Medical Sciences, Wuhan Institute of Biological Products Co. Ltd., Beijing Tian Tan Biological Products Co. Ltd., Shanghai Zhijiang Bio-pharm Co. Ltd., Bio Farma, Butantan Institute, Pasteur Institute of India, China National Biotec Group Co. Ltd. (CNBG)
Access The Complete Quadrivalent Market Report:
Quadrivalent Market Geographic Distribution And Regional Opportunities
North America was the largest region in the quadrivalent market in 2025. The regions covered in the quadrivalent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model